Información del producto
- (16Alpha)-21-{4-[2,6-Di(Pyrrolidin-1-Yl)Pyrimidin-4-Yl]Piperazin-1-Yl}-16-Methylpregna-1,4,9(11)-Triene-3,20-Dione Methanesulfonate (1:1)
- 21-(4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate
- Freedox
- Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16alpha)-, monomethanesulfonate
- Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16α), methanesulfonate (1:1)
- Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16α)-, monomethanesulfonate
- U 74006F
- U74006F
- Unii-19B418Dv39
Tirilazad mesylate is a drug used to treat chronic obstructive pulmonary disease (COPD) or bowel disease. It is a prodrug that is converted in vivo to its active form, tirofiban. Tirilazad mesylate is metabolized by cytochrome P450 enzymes and has been shown to be an experimental model for the study of antioxidant vitamin interactions with drugs. The effects of tirilazad mesylate on rat liver microsomes have been studied using metabolic models. These studies have shown that this drug causes hepatic impairment and decreases energy metabolism. This drug also has a potential for causing toxicity in the central nervous system when given subarachnoidally, which may lead to neuronal death.
Propiedades químicas
Consulta técnica sobre: 3D-FT177874 Tirilazad mesylate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
